January 22, 2015
Cosentyx, a biologic medication from Novartis, was FDA approved yesterday for the treatment of adults with moderate to severe plaque psoriasis. Plaque psoriasis, the most common form of psoriasis, appears as areas of thick, red skin that may be covered with patches of white, silvery scales or flakes.
Secukinumab, the active ingredient of Cosentyx, is an interleukin-17A inhibitor that works by inhibiting the IL-17 protein that can lead to inflammation of the skin. Cosentyx is the first medication to block IL-17 to be made available on the market.
Cosentyx is administered as a subcutaneous injection (under the skin), that may be administered with other psoriasis treatments, including phototherapy or other systemic therapy.
The FDA’s approval was based on four clinical trials involving roughly 2400 patients that compared secukinumab against a placebo. The studies found that those who were administered Cosentyx had better results than those given placebo and developed ‘clear or almost clear’ skin.
Secukinumab was approved earlier this month by the European commission as a first-line systemic treatment of moderate to severe plaque psoriasis, but may be marketed under a different brand name.
Cosentyx is the most recent biologic medication to be FDA approved for the treatment of psoriasis or psoriatic arthritis and joins the ranks of Otezla (Apremilast), Cimzia (certolizumab pegol), and Stelara (ustekinumab)
Read the FDA Press Release of the Cosentyx Approval.